Efficacy of autologous platelet-rich plasma in the treatment of vitiligo: A 10-patient prospective study.

Abstract

Vitiligo is an autoimmune disorder characterized by loss of epidermal melanocytes. It has cosmetic and psychosocial impact. The objective of this paper is to evaluate the interest of platelet-rich-plasma in the treatment of vitiligo. We conducted a prospective study between January 2019 and September 2021. Our descriptive study included 10 patients followed-up for vitiligo refractory to conventional therapies. The mean age was 36.2 years. Sex ratio was 0.25. Prior to platelet-rich-plasma treatment, vitiligo was stable in all cases. The mean number of platelet-rich-plasma sessions received by our patients was 2.6 (1-6). A visible improvement of lesions was obtained after a mean of 1.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. An improvement of more than 75% (grade 4) was noted in 2 cases after a mean duration of 5.5 sessions. 40% of patients had obtained repigmentation of more than 50% for at least one lesion. A percentage of improvement between 50 and 74% (grade 3) was obtained for 2 patients. Four patients had an improvement of less than 25% (grade 1) after a mean of 1.75 sessions. There was no recurrence of depigmentation after a mean follow-up of 6 months (1 to 24 months). Our series proves the benefit of platelet-rich-plasma in the treatment of vitiligo. It is a safe and promising option for stable lesions in different body sites with few side effects.